NICE backs Jardiance for chronic heart failure with reduced ejection fraction

4 February 2022

The National Institute for Health and Care Excellence (NICE) has recommended that Jardiance (empagliflozin), from German family-owned pharma major Boehringer Ingelheim and marketed in partnership with Eli Lilly (NYSE: LLY), will be recommended as a clinical and cost-effective treatment option for adult patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF) as an add-on to optimized standard care.

Published today, the positive Final Appraisal Document (FAD) from the UK health technology assessor means that adults with HFrEF in England and Wales will soon be able to access empagliflozin via the NHS. The NICE states that treatment should be initiated on the advice of a heart failure specialist, and monitored by the most appropriate healthcare professional.

Heart failure affects an estimated 920,000 people in the UK, most of whom (64%) have HFrEF. Heart failure is one of the leading causes of avoidable hospitalizations, associated with considerable National Health Service (NHS) resource utilization and a detrimental impact on patients’ quality of life and life expectancy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK